title: Expression of elongation factor (EF)-Tu is correlated with prognosis of gastric adenocarcinomas.
abstract: Altered expressions of mitochondria elongation factor Tu (EF-Tu) have been observed in certain types of cancers, including gastric cancer cell lines, but the impact of the alterations in gastric adenocarcinoma remains unclear. The purpose of this study was to investigate the expression of EF-Tu in gastric adenocarcinoma and to assess its clinical significance. A total of 104 paired resected gastric adenocarcinoma and corresponding normal specimens were collected in this study. EF-Tu expression was assessed by immunohistochemical staining. The correlation of EF-Tu expression and patients' clinicopathological parameters was statically evaluated and the prognostic significance of EF-Tu expression was assessed by univariate and multivariate analyses. Forty-nine out of 104 (47.1%) gastric adenocarcinoma specimens showed high expression of EF-Tu, while the remaining 55 specimens showed weak or negative expression of EF-Tu. In contrast, EF-Tu high expression was detected in 62.5% (65 of 104) normal tissues. Down-regulation of EF-Tu was associated with serosal invasion (P = 0.042) and node involvement (P = 0.005), and down-regulation of EF-Tu was correlated with poor overall survival (P = 0.020). In curative resection (R0) patients, there were also significant differences (P = 0.043). In the multivariate analysis, the EF-Tu expression remained a significant independent prognostic factor (P = 0.038). Our results indicate that EF-Tu is expressed in both gastric adenocarcinoma and corresponding normal tissues. Down-regulation of EF-Tu expression is associated with advanced disease stage and EF-Tu expression maybe served as an independent prognostic factor.
authors.affiliation: Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang, 312000, China.
authors.forename: Chaoyang
authors.initials: C
authors.lastname: Xu
authors.forename: Jianjun
authors.initials: J
authors.lastname: Wang
authors.forename: Jiajia
authors.initials: J
authors.lastname: Li
authors.forename: Rengui
authors.initials: R
authors.lastname: Fang
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015536:Down-Regulation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010444:Peptide Elongation Factor Tu / Q000378:metabolism*; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D015996:Survival Rate
chemical_list: D010444:Peptide Elongation Factor Tu
references.citation: Nat Struct Mol Biol. 2005 Sep;12(9):772-8
references.pmid: 16116436
references.citation: J Mol Biol. 2000 Dec 15;304(5):995-1005
references.pmid: 11124042
references.citation: FEBS Lett. 2006 Aug 21;580(19):4576-81
references.pmid: 16876786
references.citation: Free Radic Biol Med. 2004 Sep 1;37(5):643-53
references.pmid: 15288122
references.citation: Ann Surg. 2005 Jan;241(1):27-39
references.pmid: 15621988
references.citation: Curr Mol Med. 2007 Feb;7(1):121-31
references.pmid: 17311537
references.citation: J Biol Chem. 1998 May 8;273(19):11478-82
references.pmid: 9565560
references.citation: Cell. 2006 May 19;125(4):749-60
references.pmid: 16713565
references.citation: Cell Metab. 2006 Mar;3(3):177-85
references.pmid: 16517405
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1386-95
references.pmid: 18559553
references.citation: Int J Cancer. 1992 Mar 12;50(5):740-5
references.pmid: 1544708
references.citation: Cancer Sci. 2010 Jun;101(6):1536-42
references.pmid: 20384629
references.citation: Lancet. 2003 Jul 26;362(9380):305-15
references.pmid: 12892963
references.citation: Mol Microbiol. 2005 Apr;56(2):383-96
references.pmid: 15813732
references.citation: Parasitol Res. 2008 Sep;103(4):953-7
references.pmid: 18581140
references.citation: Proteomics. 2003 Jul;3(7):1318-24
references.pmid: 12872233
references.citation: Trends Cell Biol. 2008 Apr;18(4):165-73
references.pmid: 18296052
references.citation: J Biol Chem. 2007 Feb 9;282(6):4076-84
references.pmid: 17130126
references.citation: FEBS Lett. 1995 Jan 23;358(2):119-25
references.pmid: 7828719
references.citation: Cell Metab. 2006 Mar;3(3):187-97
references.pmid: 16517406
references.citation: Anticancer Res. 2010 Nov;30(11):4459-65
references.pmid: 21115893
references.citation: Oncogene. 1990 Jun;5(6):839-43
references.pmid: 2193292
references.citation: Proteomics. 2004 Apr;4(4):1135-44
references.pmid: 15048994
references.citation: J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S
references.pmid: 18523064
references.citation: J Plant Physiol. 2007 Dec;164(12):1564-71
references.pmid: 17766005
references.citation: Mitochondrion. 2004 Sep;4(5-6):755-62
references.pmid: 16120430
references.citation: Exp Cell Res. 2008 Jun 10;314(9):1923-8
references.pmid: 18410925
references.citation: Biochemistry. 2001 Jul 24;40(29):8531-5
references.pmid: 11456491
references.citation: Mol Cell Biol. 1988 Mar;8(3):1085-92
references.pmid: 3163409
references.citation: Free Radic Biol Med. 2007 Jul 1;43(1):117-27
references.pmid: 17561100
references.citation: Am J Physiol Cell Physiol. 2007 Aug;293(2):C761-71
references.pmid: 17537807